ECSP13013043A - ORAL LIQUID COMPOSITION THAT INCLUDES DIVALPROEX SODIUM AND PROCESS TO PREPARE THE SAME - Google Patents

ORAL LIQUID COMPOSITION THAT INCLUDES DIVALPROEX SODIUM AND PROCESS TO PREPARE THE SAME

Info

Publication number
ECSP13013043A
ECSP13013043A ECSP13013043A ECSP13013043A EC SP13013043 A ECSP13013043 A EC SP13013043A EC SP13013043 A ECSP13013043 A EC SP13013043A EC SP13013043 A ECSP13013043 A EC SP13013043A
Authority
EC
Ecuador
Prior art keywords
divalproex sodium
prepare
liquid composition
same
oral liquid
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Dipak Sahana
Prasad Patil
Ganesh Narayan Phadtare
Manish Grover
Shripad Jathar
Original Assignee
Abbott Healthcare Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46939730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13013043(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Healthcare Pvt Ltd filed Critical Abbott Healthcare Pvt Ltd
Publication of ECSP13013043A publication Critical patent/ECSP13013043A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige a una composición oral, líquida de sabor agradable, que comprende sodio de divalproex, y a un proceso para preparar la misma. Particularmente, la presente invención se refiere a una composición oral, líquida, estable, tal como una solución que comprende sodio de divalproex y a un proceso para preparar la misma.The present invention is directed to an oral, liquid composition of pleasant taste, comprising divalproex sodium, and to a process for preparing it. Particularly, the present invention relates to a stable, liquid, oral composition, such as a solution comprising divalproex sodium and a process for preparing it.

ECSP13013043 2011-05-02 2013-11-25 ORAL LIQUID COMPOSITION THAT INCLUDES DIVALPROEX SODIUM AND PROCESS TO PREPARE THE SAME ECSP13013043A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1365MU2011 2011-05-02

Publications (1)

Publication Number Publication Date
ECSP13013043A true ECSP13013043A (en) 2014-01-31

Family

ID=46939730

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13013043 ECSP13013043A (en) 2011-05-02 2013-11-25 ORAL LIQUID COMPOSITION THAT INCLUDES DIVALPROEX SODIUM AND PROCESS TO PREPARE THE SAME

Country Status (6)

Country Link
BR (1) BR112013027685A2 (en)
CL (1) CL2013003137A1 (en)
CO (1) CO6801771A2 (en)
EC (1) ECSP13013043A (en)
MX (1) MX2013012827A (en)
WO (1) WO2012150607A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104248627A (en) * 2013-06-25 2014-12-31 北大方正集团有限公司 Valproate semisodium-containing effervescent dry suspension and preparation method thereof
BE1026024B1 (en) * 2018-02-16 2019-09-16 Neogen Nv Method for preparing a solution comprising valproic acid and / or one or more of its salts, said solution and use
CN114760976A (en) 2019-12-16 2022-07-15 高露洁-棕榄公司 Oral care composition containing inulin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
FR2643556B1 (en) 1989-02-27 1993-03-05 Sanofi Sa PHARMACEUTICAL COMPOSITION WITH SUSTAINED RELEASE OF VALPROIC ACID
US6419953B1 (en) 1998-12-18 2002-07-16 Abbott Laboratories Controlled release formulation of divalproex sodium
US6511678B2 (en) 1998-12-18 2003-01-28 Abbott Laboratories Controlled release formulation of divalproex sodium
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
US6528090B2 (en) 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US6610326B2 (en) * 2001-02-16 2003-08-26 Andrx Corporation Divalproex sodium tablets
US20070082046A1 (en) * 2005-10-11 2007-04-12 Banner Pharmacaps, Inc. Enteric valproic acid
US20110015267A1 (en) * 2009-07-20 2011-01-20 Deanna Jean Nelson Methods for the preparation and use of aqueous solutions of magnesium valproate hydrate and l-carnitine

Also Published As

Publication number Publication date
WO2012150607A2 (en) 2012-11-08
WO2012150607A3 (en) 2013-02-14
CL2013003137A1 (en) 2014-08-01
MX2013012827A (en) 2014-02-11
CO6801771A2 (en) 2013-11-29
BR112013027685A2 (en) 2016-12-27

Similar Documents

Publication Publication Date Title
CY1116987T1 (en) Concentrated imidazolylimidazoles as antiviral compounds
IN2015KN00262A (en)
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
MX353706B (en) ANTIBODIES AGAINST HUMAN CSF-1R AND USES OF THE SAME.
CL2016001150A1 (en) Solid forms of [(5- (3-chlorophenyl) -3-hydroxypyridin-2-carbonyl] acetic acid, compositions, and uses thereof.
UY33735A (en) ANTIVIRAL COMPOUNDS
MX2019003738A (en) ANTIVIRAL COMPOUNDS.
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
UA116999C2 (en) SELECTED HEMAGLUTIN ANTIBODY AND PHARMACEUTICAL COMPOSITION TO BE CONTAINED
MX340147B (en) Pharmaceutical and nutraceutical compositions of abscisic acid.
EA201391488A1 (en) COMPOSITIONS WITH REDUCED VISCOSITY
MX2019012939A (en) Linaclotide-containing formulations for oral administration.
UA116889C2 (en) COMPOSITION COMPRISING A MIXTURE OF CD95-Fc ISOFORMS
IN2014MN00859A (en)
EA029539B8 (en) Pharmaceutical composition of sitagliptin
EA201592227A1 (en) STABLE SOLUTIONS OF UNITED ACTIVE PHARMACEUTICAL INGREDIENTS FOR ORAL APPLICATION
MX2014010433A (en) Novel crystalline form of sitagliptin sulfate.
BR112012032248A2 (en) 5-ethyl-2- {4 - [- 4- (-4-tetrazol-1-yl-phenoxymethyl) -thiazol-2-yl] -piperidin-1-yl} -pyrimidine compositions
MX2015009617A (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoq uinoline-3-carbonyl]-amino}-acetic acid.
CO6321288A2 (en) SALES OF HIV INHIBITING COMPOUNDS
ECSP13013043A (en) ORAL LIQUID COMPOSITION THAT INCLUDES DIVALPROEX SODIUM AND PROCESS TO PREPARE THE SAME
IN2015DN04074A (en)
IN2014DN03245A (en)
MX358995B (en) Stabilised amorphous form of agomelatine, a process for its preparation and pharmaceutical compositions containing it.
GT201200066A (en) NEW DIHIDRO-OXAZOLOBENZODIAZEPINONAS DERIVATIVES, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM